Costs and persistence of carbonic anhydrase inhibitor versus alpha‑2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK‑GPRD database^*

References

• Owen CG, Carey IM, De Wilde S, et al. The epidemiology of medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994 to 2003. Br J Ophthalmol 2006;90:861–8
   PubMed Web of Science ®Google Scholar
• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262–7
   PubMed Web of Science ®Google Scholar
• Friedman DS, Wolfs RC, O’Colmain BJ, et al.; Eye Diseases Prevalence Research Group. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004;122:532–8
   Google Scholar
• Coyle D, Drummond M. The economic burden of glaucoma in the UK. The need for a far-sighted policy. Pharmacoeconomics 1995;7:484–9
   Google Scholar
• Kobelt G, Jonsson L, Gerdtham U, Krieglstein GK. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol 1998;236:811–21
   PubMed Web of Science ®Google Scholar
• Denis P, Lafuma A, Berdeaux G. Medical predictive factors of glaucoma treatment costs. J Glaucoma 2004;13:283–90
   PubMed Web of Science ®Google Scholar
• Kooner KS, Zimmerman TJ. The cost of antiglaucoma medications. Ann Ophthalmol 1987;19:327–8
   PubMed Web of Science ®Google Scholar
• Vold SD, Riggs WL, Jackimiec J. Cost analysis of glaucoma medications: a 3-year review. J Glaucoma 2002;11: 354–8
   Google Scholar
• Fiscella RG, Geller JL, Gryz LL, et al. Cost considerations of medical therapy for glaucoma. Am J Ophthalmol 1999;128:426–33
   PubMed Web of Science ®Google Scholar
• Jönsson B, Krieglstein G. Primary open-angle glaucoma-differences in international treatment patterns and costs. Oxford: Isis Medical Media Ltd, 1998
   Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701–13
   PubMed Web of Science ®Google Scholar
• The European Glaucoma Prevention Study (EGPS) group. Results of the European Glaucoma Prevention Study. Ophthalmology 2005;112:366–75
   Google Scholar
• The AGIS investigators. The Advanced Glaucoma Intervention Study (AGIS). Report #13: Comparison of treatment outcomes within race: 10-year results. Ophthalmology 2004;111: 651–64
   Google Scholar
• Heijl A, Leske MC, Bengtsson B, et al. Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268–79
   Google Scholar
• Leske MC, Heijl A, Hussein M, et al. Early Manifest Glaucoma Trial Group Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121:48–56
   PubMed Web of Science ®Google Scholar
• Vidal. Edition du Vidal 2006. Paris, France
   Google Scholar
• Terminology and Guidelines for Glaucoma. The European Glaucoma Society, 2nd edn. Savona, Italy: Dogma. Available at: http://www.eugs.org/ebook.asp [last access:26/02/2008]
   Google Scholar
• American Academy of Ophthalmology Glaucoma Panel. Preferred practice pattern. Primary open angle glaucoma. San Francisco: American Academy of Ophthalmology, 2003:1–36
   Google Scholar
• Stewart WC, Sharpe ED, Harbin TS, et al. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure. Am J Ophthalmol 2000;129: 723–7
   Google Scholar
• Whitson JT, Henry C, Hughes B, et al. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Glaucoma 2004;13:168–73
   PubMed Web of Science ®Google Scholar
• Hjelmgren J, Berggren F, Andersson D. Health Economics guidelines – Similarities, differences and some implications. Value Health 2001;4:225–50
   Google Scholar
• Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005;112:863–8
   PubMed Web of Science ®Google Scholar
• Deschaseaux-Voinet C, Lafuma A, Berdeaux G. Cost and effectiveness of brinzolamide versus dorzolamide in current practice: an analysis based on the UK-GPRD data base. J Med Econom 2003:6:69–78
   Google Scholar
• Wilensky J, Fiscella RG, Carlson AM, et al. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol 2006;141(1 Suppl):S28–33
   PubMed Web of Science ®Google Scholar
• Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005;140:598–606
   PubMed Web of Science ®Google Scholar
• Rait JL, Adena MA. Persistency rates for prostaglandin and other hypotensive eyedrops: population-based study using pharmacy claims data. Clin Exp Ophthalmol 2007;35:602–11
   PubMed Web of Science ®Google Scholar
• Reardon G, Schwartz GF, Mozaffari E. Patient persistency with ocular prostaglandin therapy: a population based, retrospective study. Clin Ther 2003;25:1172–85
   Google Scholar
• Friedman DS, Quigley HA, Gelb A, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthamol Vis Sci 2007;48:5052–7
   PubMed Web of Science ®Google Scholar
• Quigley HA, Friedman DS, Hahn SR. Evaluation of practice patterns for care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study. Ophthalmology 2007;114:1599–606
   Google Scholar
• http://www.gprd.com/home/. Accessed July 2007
   Google Scholar
• Yue LQ. Statistical and regulatory issues with the application of propensity score analysis to nonrandomized medical device clinical studies. J Biopharm Stat 2007;17:1–13; Discussion 15–17, 19–21, 23–7 passim
   Google Scholar
• British National Formulary, 49th edn. London: British Medical Journal and Royal Pharmaceutical Society, 2005. www.bnf.com
   Google Scholar
• Statistics of OECD http://www.oecd.org/. Accessed July 2007
   Google Scholar
• Curtis L, Netten A. Units costs of health and social care 2005 PSSRU University of Kent. (http://www.pssru.ac.uk/). Accessed July 2007
   Google Scholar
• Roulland JF, Le Pen C, Gouveia Pinto C, et al. Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma: in four European countries. Pharmacoeconomics 2003;21:201–13
   PubMed Web of Science ®Google Scholar
• Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005;112:863–8
   PubMed Web of Science ®Google Scholar
• Platt R, Reardon G, Mozaffari E. Observed time between prescription refills for newer ocular hypotensive agents: the effect of bottle size. Am J Ophthalmol 2004;137(1 Suppl):S17–23
   Google Scholar
• Directive 92/26/CEE du conseil du 31 Mars 1992, concernant la classification en matière de délivrance des médicaments à usage hume. Journal officiel n° L 113 du 30/04/1992
   Google Scholar
• Hylton C, Robin AL. Update on prostaglandin analogs. Curr Opin Ophthalmol 2003;14:65–9
   PubMedGoogle Scholar